Published: June 2017
Report Code: LS11024
Category : Pharmaceuticals
Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation
Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
Some of the symptoms associated with oral mucositis are open sores or bleeding, pain, redness or swelling, white patches, dry mouth, diarrhea, nausea, blood in mouth, thicker saliva in the mouth and difficulty in talking or swallowing. Oral mucositis can be treated by using antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses and mucosal coating agents.
ORAL MUCOSITIS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
Drug manufacturing companies are constantly in the quest to find better and new treatment strategies with potential targets such as glucocorticoid receptor and superoxide dismutase which can also prove to be effective in oral mucositis treatment. The U.S. Food and Drug Administration (USFDA) has granted various designations including orphan drug and fast track status to many drugs which are driving the growth of the pipeline.
As of May 2017, the oral mucositis pipeline comprises approximately 18 active drug candidates in different stages of development.
Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes: